Lunai Bioworks (LNAI) Total Debt (2011 - 2025)

Lunai Bioworks (LNAI) posted quarterly Total Debt of $1.3 million for Q4 2025, up 20.38% quarter-over-quarter from $1.0 million in Q3 2025.

Lunai Bioworks (LNAI) Total Debt (2011 - 2025) Analysis & Trends

Lunai Bioworks' Total Debt history runs 9 years deep, the most recent figure standing at $1.3 million for Q4 2025.

In Q4 2025, Total Debt changed N/A year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $3.6 million, changed N/A from the prior year.
Total Debt for Q4 2025 stood at $1.3 million, up from $1.0 million in the prior quarter.
The five-year high for Total Debt was $7.5 million in Q1 2021, with the low at $1.0 million in Q3 2025.
The 3-year median for Total Debt is $4.6 million (2021), against an average of $4.0 million.
Peak annual rise in Total Debt reached 14.47% in 2021, while the deepest fall reached 41.02% in 2021.
Lunai Bioworks' Total Debt stood at $4.7 million in 2021, then decreased by 0.03% to $4.7 million in 2022, then slumped by 73.13% to $1.3 million in 2025.
Business Quant data shows LNAI's Total Debt at $1.3 million in Q4 2025, $1.0 million in Q3 2025, and $3.6 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.34 Bn
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00	-

Download Data